Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
This is not a financial advice!
2 upcoming catalysts on 31st...
Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens. Neoantigens are protein markers unique to each individual that are expressed on the surface of every cancer cell and can be detected by the immune system. Achilles uses DNA sequencing data from each patient together with its proprietary...
Achilles Therapeutics PLC (NASDAQ:ACHL) is another undervalued small bio cancer play like PHIO with $6 per share in cash and many upcoming catalysts and presentations. Low risk swing from here. Watch the break of the declining EMA50 on volume for a strong rally to the EMA200 that lies at 6.21 I have been accumulating.
